An Italian cost-effectiveness analysis of paclitaxel albumin (nab®-paclitaxel) plus gemcitabine vs gemcibatine alone for metastatic pancreatic cancer patients: The APICE study

被引：0
|
作者：
Lazzaro, C. [1 ]
Barone, C. [2 ]
Caprioni, F. [3 ]
Cascinu, S. [4 ]
Falcone, A. [5 ]
Maiello, E. [6 ]
Milella, M. [7 ]
Pinto, C. [8 ]
Reni, M. [9 ]
Tortora, G. [10 ]
机构：
[1] Studio Econ Sanit, Pharmacoecon, Milan, Italy
[2] Policlin Univ A Gemelli, UOC Oncol Med, Med Interna, Rome, Italy
[3] IST Ist Nazl Ric Canc, IRCCS AOU San Martino, Oncol Med 1, Genoa, Italy
[4] Azienda Osped Univ Policlin Modena, Med Oncol, Modena, Italy
[5] Azienda Osped Univ S Chiara, Dept Oncol Presidio Ospedaliero, Pisa, Italy
[6] IRCCS Casa Sollievo Sofferenza, Dept Hematol Oncol, San Giovanni Rotondo, Italy
[7] Ist Regina Elena, SC Oncol Med A, Rome, Italy
[8] Azienda Osped Arcispedale Santa Maria Nuova IRCCS, SC Oncol, Reggio Emilia, Italy
[9] IRCCS San Raffaele, Med Oncol, Milan, Italy
[10] Azienda Osped Univ Integrata Verona Borgo Roma, Med Oncol, Verona, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw377.24
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1045P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Clinical and translational results of a phase I study, tocilizumab plus gemcitabine/nab-paclitaxel in patient with gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    Aoki, Kazunori
    Yamaguchi, Kyoko
    Sawada, Noriaki
    Fujii, Etsuko
    Nishidate, Masanobu
    Fujitomo, Takashi
    Mizuno, Hideaki
    Kayukawa, Yoko
    Kato, Atsuhiko
    Makikawa, Mayu
    Imaoka, Hiroshi
    Sasaki, Mitsuhito
    Watanabe, Kazuo
    Tsunoda, Hiroyuki
    Terao, Kimio
    Ochiai, Atsushi
    CANCER RESEARCH, 2022, 82 (12)
  • [42] Cost-effectiveness of nanoparticle albumin-bound (nab) paclitaxel (ABX) vs Cremophor-based paclitaxel (CP) in the treatment of metastatic breast cancer (MBC).
    Gradishar, W
    Wolinsky, S
    Vishalpura, T
    Nightengale, B
    Bramley, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 36S - 36S
  • [43] Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
    Grierson, Patrick M.
    Tan, Benjamin
    Pedersen, Katrina S.
    Park, Haeseong
    Suresh, Rama
    Amin, Manik A.
    Trikalinos, Nikolaos A.
    Knoerzer, Deborah
    Kreider, Brent
    Reddy, Anupama
    Liu, Jingxia
    Der, Channing J.
    Wang-Gillam, Andrea
    Lim, Kian-Huat
    ONCOLOGIST, 2023, 28 (02): : E115 - E123
  • [44] Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study
    Catalano, Martina
    Roviello, Giandomenico
    Conca, Raffaele
    D'Angelo, Alberto
    Palmieri, Valeria Emma
    Panella, Benedetta
    Petrioli, Roberto
    Ianza, Anna
    Nobili, Stefania
    Mini, Enrico
    Ramello, Monica
    CURRENT CANCER DRUG TARGETS, 2020, 20 (11) : 887 - 895
  • [45] Observational study of comparative effectiveness of nab-paclitaxel plus gemcitabine vs gemcitabine plus cisplatin or gemcitabine alone for the first-line treatment of metastatic pancreatic adenocarcinoma in the University Hospital Centre Zagreb
    Prejac, J.
    Gorsic, I.
    Vidovic, M.
    Golem, H.
    Kekez, D.
    Librenjak, N.
    Plestina, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 46 - 46
  • [46] A phase II study of nab-paclitaxel and gemcitabine in Korean patients with metastatic pancreatic cancer
    Lee, S. J.
    Oh, D-Y.
    Kang, J-H.
    Choi, H. J.
    Lee, M. A.
    Oh, S. Y.
    Kim, S-T.
    Park, Y. S.
    Ryu, B-Y.
    Park, J. O.
    ANNALS OF ONCOLOGY, 2018, 29
  • [47] A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study
    Nakazawa, J.
    Otsuka, T.
    Shimokawa, M.
    Koga, F.
    Ueda, Y.
    Otsu, S.
    Arima, S.
    Fukahori, M.
    Makiyama, A.
    Taguchi, H.
    Honda, T.
    Shibuki, T.
    Shirakawa, T.
    Mitsugi, K.
    Nio, K.
    Ide, Y.
    Ureshino, N.
    ANNALS OF ONCOLOGY, 2019, 30
  • [48] Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer
    David, Goldstein
    Daniel, Von Hoff
    Chiorean, E.
    Michele, Reni
    Josep, Tabernero
    Ramesh, Ramanathan
    Julia, Wilkerson
    Marc, Botteman
    Abdalla, Aly
    Sandra, Margunato-Debay
    Brian, Lu
    Chrystal, Louis
    Markus, Renschler
    Desmond, McGovern
    Chee, Lee
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Chen, Shuling
    Li, Jiaxin
    Dong, Aoran
    Liu, Zelong
    Zhu, Meiyan
    Jin, Meng
    Wei, Guangyan
    Wu, Shuang
    Wang, Yan
    Chen, Yong
    Peng, Zhenwei
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [50] NAB-PACLITAXEL PLUS GEMCITABINE VS GEMCITABINE ALONE FOR PATIENTS WITH METASTATIC PANCREATIC CANCER: INFLUENCE OF PRIMARY PANCREATIC TUMOR LOCATION ON EFFICACY AND TREATMENT EXPOSURE IN THE MPACT PHASE III TRIAL
    Jose, Lopez-Martin
    Wee, Ma Wen
    Christos, Karapetis
    Peter, Balcke
    Hagan, Kennecke
    Michael, Stahl
    Michele, Milella
    Francis, Nugent
    Diane, Prager
    Brian, Lu
    Stefano, Ferrara
    Darryl, Penenberg
    Daniel, Von Hoff
    ANNALS OF ONCOLOGY, 2014, 25 : 28 - 28
12345